This week’s Q2 update and conference call by Prometic highlighted just how important a part one of the Company’s smallest investigational indications (Alström Syndrome) is playing in driving its partnering and clinical strategy. Why is this?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
This week’s Q2 update and conference call by Prometic highlighted just how important a part one of the Company’s smallest investigational indications (Alström Syndrome) is playing in driving its partnering and clinical strategy. Why is this?
